The risk of developing grade III–IV checkpoint inhibitor colitis (CIC) in patients receiving CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, or the combination is 8%, 1–2%, and 11%, respectively [5–7]. The gene discussed is PDCD1; the disease is colitis.